Relay Therapeutics, Inc. leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety & efficacy. Learn more ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

New research reveals how tiny electrical gates in the brain, known as NMDA receptors, control learning, memory, and neuron ...

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial ...

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced the appointment of Timothy Noyes as President and ...

Subject to the terms of the Rights Plan, the rights will expire on October 27, 2026, unless the rights are earlier redeemed or exchanged by Neuphoria. Additional information regarding the Rights Plan ...

Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments ...

The National Academy of Medicine (NAM) has elected Mohammed K. Ali, MD, MSc, Stephen F. Traynelis, PhD, Wanda Barfield, MD, MPH, and Ravi Thadhani ...

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical and preclinical ...

Seventh paragraph, second sentence of release issued October 24, 2025, should read: "a disease control rate (DCR) of 83%" ...

Sudo Biosciences, ("Sudo"), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced positive topline results from ...